CA2821515A1 - Anti-ngf compositions and use thereof - Google Patents
Anti-ngf compositions and use thereof Download PDFInfo
- Publication number
- CA2821515A1 CA2821515A1 CA2821515A CA2821515A CA2821515A1 CA 2821515 A1 CA2821515 A1 CA 2821515A1 CA 2821515 A CA2821515 A CA 2821515A CA 2821515 A CA2821515 A CA 2821515A CA 2821515 A1 CA2821515 A1 CA 2821515A1
- Authority
- CA
- Canada
- Prior art keywords
- pain
- antibody
- seq
- ngf
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims description 79
- 238000000034 method Methods 0.000 claims abstract description 418
- 239000012634 fragment Substances 0.000 claims abstract description 287
- 229920001184 polypeptide Polymers 0.000 claims abstract description 161
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 161
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 161
- 101150111783 NTRK1 gene Proteins 0.000 claims abstract description 125
- 230000027455 binding Effects 0.000 claims abstract description 81
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 52
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 52
- 239000002157 polynucleotide Substances 0.000 claims abstract description 52
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 230000003993 interaction Effects 0.000 claims abstract description 19
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 814
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 810
- 208000002193 Pain Diseases 0.000 claims description 460
- 230000036407 pain Effects 0.000 claims description 435
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 143
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 143
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 102
- 239000003795 chemical substances by application Substances 0.000 claims description 94
- 206010005949 Bone cancer Diseases 0.000 claims description 69
- 208000018084 Bone neoplasm Diseases 0.000 claims description 69
- 239000005557 antagonist Substances 0.000 claims description 60
- 230000002401 inhibitory effect Effects 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 57
- 210000000988 bone and bone Anatomy 0.000 claims description 55
- 208000004296 neuralgia Diseases 0.000 claims description 48
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 46
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 41
- 241000282414 Homo sapiens Species 0.000 claims description 40
- 208000035475 disorder Diseases 0.000 claims description 37
- 208000004454 Hyperalgesia Diseases 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 32
- 230000001684 chronic effect Effects 0.000 claims description 32
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 32
- 230000000284 resting effect Effects 0.000 claims description 31
- 230000002757 inflammatory effect Effects 0.000 claims description 30
- 208000004550 Postoperative Pain Diseases 0.000 claims description 29
- 230000001668 ameliorated effect Effects 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 29
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 29
- 208000021722 neuropathic pain Diseases 0.000 claims description 26
- 150000003384 small molecules Chemical class 0.000 claims description 26
- 208000014674 injury Diseases 0.000 claims description 24
- 206010019233 Headaches Diseases 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 22
- 208000019695 Migraine disease Diseases 0.000 claims description 22
- 230000004054 inflammatory process Effects 0.000 claims description 22
- 206010027599 migraine Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 208000009935 visceral pain Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 20
- 238000001727 in vivo Methods 0.000 claims description 20
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 19
- 208000027418 Wounds and injury Diseases 0.000 claims description 19
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 18
- 208000035154 Hyperesthesia Diseases 0.000 claims description 17
- 206010053552 allodynia Diseases 0.000 claims description 17
- 206010058019 Cancer Pain Diseases 0.000 claims description 16
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 16
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 16
- 230000008733 trauma Effects 0.000 claims description 16
- 210000005253 yeast cell Anatomy 0.000 claims description 16
- 206010065390 Inflammatory pain Diseases 0.000 claims description 15
- 206010033645 Pancreatitis Diseases 0.000 claims description 15
- 201000006549 dyspepsia Diseases 0.000 claims description 15
- 230000002496 gastric effect Effects 0.000 claims description 15
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 15
- 201000008482 osteoarthritis Diseases 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- -1 fofecoxib Chemical compound 0.000 claims description 13
- 201000007094 prostatitis Diseases 0.000 claims description 13
- 241000235648 Pichia Species 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 238000007920 subcutaneous administration Methods 0.000 claims description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 11
- 206010052428 Wound Diseases 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 208000000094 Chronic Pain Diseases 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 230000009278 visceral effect Effects 0.000 claims description 10
- 230000000202 analgesic effect Effects 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 208000008930 Low Back Pain Diseases 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 231100000869 headache Toxicity 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 230000003187 abdominal effect Effects 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 229920003169 water-soluble polymer Polymers 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 230000028709 inflammatory response Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 3
- 241000235058 Komagataella pastoris Species 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims 38
- 208000011580 syndromic disease Diseases 0.000 claims 28
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 26
- 231100000599 cytotoxic agent Toxicity 0.000 claims 26
- 239000000463 material Substances 0.000 claims 26
- 239000012857 radioactive material Substances 0.000 claims 26
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 21
- 229940124597 therapeutic agent Drugs 0.000 claims 21
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 21
- 230000013595 glycosylation Effects 0.000 claims 15
- 238000006206 glycosylation reaction Methods 0.000 claims 15
- 208000030507 AIDS Diseases 0.000 claims 14
- 208000001387 Causalgia Diseases 0.000 claims 14
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 14
- 206010016059 Facial pain Diseases 0.000 claims 14
- 208000001640 Fibromyalgia Diseases 0.000 claims 14
- 208000028911 Temporomandibular Joint disease Diseases 0.000 claims 14
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 claims 14
- 208000005298 acute pain Diseases 0.000 claims 14
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 14
- 230000002980 postoperative effect Effects 0.000 claims 14
- 230000002792 vascular Effects 0.000 claims 14
- 108090001008 Avidin Proteins 0.000 claims 13
- 101710112752 Cytotoxin Proteins 0.000 claims 13
- 108090000790 Enzymes Proteins 0.000 claims 13
- 102000004190 Enzymes Human genes 0.000 claims 13
- 108010090804 Streptavidin Proteins 0.000 claims 13
- 229960002685 biotin Drugs 0.000 claims 13
- 235000020958 biotin Nutrition 0.000 claims 13
- 239000011616 biotin Substances 0.000 claims 13
- 229940127089 cytotoxic agent Drugs 0.000 claims 13
- 239000002254 cytotoxic agent Substances 0.000 claims 13
- 239000002619 cytotoxin Substances 0.000 claims 13
- 229940088598 enzyme Drugs 0.000 claims 13
- 239000007850 fluorescent dye Substances 0.000 claims 13
- 239000000758 substrate Substances 0.000 claims 13
- 208000000450 Pelvic Pain Diseases 0.000 claims 12
- 125000000539 amino acid group Chemical group 0.000 claims 12
- 208000013507 chronic prostatitis Diseases 0.000 claims 12
- 210000005260 human cell Anatomy 0.000 claims 12
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 12
- 230000017854 proteolysis Effects 0.000 claims 12
- 239000003381 stabilizer Substances 0.000 claims 12
- 239000003937 drug carrier Substances 0.000 claims 11
- 239000003242 anti bacterial agent Substances 0.000 claims 10
- 230000001387 anti-histamine Effects 0.000 claims 10
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 10
- 239000002260 anti-inflammatory agent Substances 0.000 claims 10
- 229940088710 antibiotic agent Drugs 0.000 claims 10
- 229940125715 antihistaminic agent Drugs 0.000 claims 10
- 239000000739 antihistaminic agent Substances 0.000 claims 10
- 208000007848 Alcoholism Diseases 0.000 claims 7
- 208000006820 Arthralgia Diseases 0.000 claims 7
- 208000014181 Bronchial disease Diseases 0.000 claims 7
- 206010062746 Carditis Diseases 0.000 claims 7
- 206010064012 Central pain syndrome Diseases 0.000 claims 7
- 208000006561 Cluster Headache Diseases 0.000 claims 7
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 7
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 7
- 208000016192 Demyelinating disease Diseases 0.000 claims 7
- 201000004624 Dermatitis Diseases 0.000 claims 7
- 206010012434 Dermatitis allergic Diseases 0.000 claims 7
- 206010072132 Fracture pain Diseases 0.000 claims 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 7
- 201000005569 Gout Diseases 0.000 claims 7
- 208000009889 Herpes Simplex Diseases 0.000 claims 7
- 206010020853 Hypertonic bladder Diseases 0.000 claims 7
- 208000009525 Myocarditis Diseases 0.000 claims 7
- 201000002481 Myositis Diseases 0.000 claims 7
- 206010029240 Neuritis Diseases 0.000 claims 7
- 208000001132 Osteoporosis Diseases 0.000 claims 7
- 208000001164 Osteoporotic Fractures Diseases 0.000 claims 7
- 208000004983 Phantom Limb Diseases 0.000 claims 7
- 206010056238 Phantom pain Diseases 0.000 claims 7
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 7
- 208000003251 Pruritus Diseases 0.000 claims 7
- 201000004681 Psoriasis Diseases 0.000 claims 7
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 7
- 208000025747 Rheumatic disease Diseases 0.000 claims 7
- 206010039085 Rhinitis allergic Diseases 0.000 claims 7
- 208000008765 Sciatica Diseases 0.000 claims 7
- 208000006011 Stroke Diseases 0.000 claims 7
- 206010042496 Sunburn Diseases 0.000 claims 7
- 206010043269 Tension headache Diseases 0.000 claims 7
- 208000008548 Tension-Type Headache Diseases 0.000 claims 7
- 208000025865 Ulcer Diseases 0.000 claims 7
- 206010047642 Vitiligo Diseases 0.000 claims 7
- 206010000269 abscess Diseases 0.000 claims 7
- 201000010105 allergic rhinitis Diseases 0.000 claims 7
- 238000002266 amputation Methods 0.000 claims 7
- 206010003246 arthritis Diseases 0.000 claims 7
- 208000006673 asthma Diseases 0.000 claims 7
- 238000002512 chemotherapy Methods 0.000 claims 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims 7
- 208000018912 cluster headache syndrome Diseases 0.000 claims 7
- 206010009887 colitis Diseases 0.000 claims 7
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- 208000000718 duodenal ulcer Diseases 0.000 claims 7
- 210000000981 epithelium Anatomy 0.000 claims 7
- 208000030533 eye disease Diseases 0.000 claims 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 7
- 208000021646 inflammation of heart layer Diseases 0.000 claims 7
- 230000004968 inflammatory condition Effects 0.000 claims 7
- 206010025135 lupus erythematosus Diseases 0.000 claims 7
- 230000001394 metastastic effect Effects 0.000 claims 7
- 206010061289 metastatic neoplasm Diseases 0.000 claims 7
- 230000004899 motility Effects 0.000 claims 7
- 210000002346 musculoskeletal system Anatomy 0.000 claims 7
- 238000002360 preparation method Methods 0.000 claims 7
- 230000000451 tissue damage Effects 0.000 claims 7
- 231100000827 tissue damage Toxicity 0.000 claims 7
- 230000009092 tissue dysfunction Effects 0.000 claims 7
- 239000003053 toxin Substances 0.000 claims 7
- 231100000765 toxin Toxicity 0.000 claims 7
- 108700012359 toxins Proteins 0.000 claims 7
- 230000036269 ulceration Effects 0.000 claims 7
- 230000001457 vasomotor Effects 0.000 claims 7
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 7
- 230000029663 wound healing Effects 0.000 claims 7
- LOWWSYWGAKCKLG-UHFFFAOYSA-N 2-(6-methoxynaphthalen-1-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC2=CC(OC)=CC=C21 LOWWSYWGAKCKLG-UHFFFAOYSA-N 0.000 claims 6
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 claims 6
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 claims 6
- 206010000087 Abdominal pain upper Diseases 0.000 claims 6
- 208000008035 Back Pain Diseases 0.000 claims 6
- 206010005063 Bladder pain Diseases 0.000 claims 6
- AJFTZWGGHJXZOB-UHFFFAOYSA-N DuP 697 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)SC(Br)=C1 AJFTZWGGHJXZOB-UHFFFAOYSA-N 0.000 claims 6
- 208000004483 Dyspareunia Diseases 0.000 claims 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010071289 Lower urinary tract symptoms Diseases 0.000 claims 6
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 6
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 6
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 claims 6
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 6
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 6
- 206010028836 Neck pain Diseases 0.000 claims 6
- 206010037779 Radiculopathy Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 206010039491 Sarcoma Diseases 0.000 claims 6
- 206010050822 Suprapubic pain Diseases 0.000 claims 6
- 206010046461 Urethral pain Diseases 0.000 claims 6
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 6
- 229960000590 celecoxib Drugs 0.000 claims 6
- 229960001259 diclofenac Drugs 0.000 claims 6
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 6
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 6
- 229960000616 diflunisal Drugs 0.000 claims 6
- 206010013990 dysuria Diseases 0.000 claims 6
- 229950005722 flosulide Drugs 0.000 claims 6
- 229950007979 flufenisal Drugs 0.000 claims 6
- 229960001680 ibuprofen Drugs 0.000 claims 6
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 claims 6
- 229950002252 isoxicam Drugs 0.000 claims 6
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 6
- 229960000991 ketoprofen Drugs 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 229960003803 meclofenamic acid Drugs 0.000 claims 6
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 6
- 229960001929 meloxicam Drugs 0.000 claims 6
- CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 claims 6
- 229960004270 nabumetone Drugs 0.000 claims 6
- 229940090008 naprosyn Drugs 0.000 claims 6
- 229960002009 naproxen Drugs 0.000 claims 6
- 229960000965 nimesulide Drugs 0.000 claims 6
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 6
- 201000008968 osteosarcoma Diseases 0.000 claims 6
- 210000003899 penis Anatomy 0.000 claims 6
- 210000002640 perineum Anatomy 0.000 claims 6
- 229960002702 piroxicam Drugs 0.000 claims 6
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 6
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 6
- 210000004706 scrotum Anatomy 0.000 claims 6
- 229950005175 sudoxicam Drugs 0.000 claims 6
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 6
- 229960000894 sulindac Drugs 0.000 claims 6
- 210000001550 testis Anatomy 0.000 claims 6
- 229960001017 tolmetin Drugs 0.000 claims 6
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 6
- 241000320412 Ogataea angusta Species 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108090000526 Papain Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102000053391 human F Human genes 0.000 claims 3
- 108700031895 human F Proteins 0.000 claims 3
- 229940055729 papain Drugs 0.000 claims 3
- 235000019834 papain Nutrition 0.000 claims 3
- 241001508785 Arxiozyma Species 0.000 claims 2
- 241000178289 Botryozyma Species 0.000 claims 2
- 241000722885 Brettanomyces Species 0.000 claims 2
- 241001508787 Citeromyces Species 0.000 claims 2
- 241000235035 Debaryomyces Species 0.000 claims 2
- 241001465321 Eremothecium Species 0.000 claims 2
- 241000235644 Issatchenkia Species 0.000 claims 2
- 241001233945 Kazachstania Species 0.000 claims 2
- 241000235649 Kluyveromyces Species 0.000 claims 2
- 241001302784 Kodamaea Species 0.000 claims 2
- 241001508815 Lodderomyces Species 0.000 claims 2
- 241001452677 Ogataea methanolica Species 0.000 claims 2
- 241000235652 Pachysolen Species 0.000 claims 2
- 208000020584 Polyploidy Diseases 0.000 claims 2
- 241000235070 Saccharomyces Species 0.000 claims 2
- 241001149673 Saturnispora Species 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 241000183049 Tetrapisispora Species 0.000 claims 2
- 241000235006 Torulaspora Species 0.000 claims 2
- 241000235152 Williopsis Species 0.000 claims 2
- 241000235017 Zygosaccharomyces Species 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 102000046917 human NGF Human genes 0.000 claims 2
- 238000011503 in vivo imaging Methods 0.000 claims 2
- 230000013011 mating Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 101100174574 Mus musculus Pikfyve gene Proteins 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 abstract description 13
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 229940053128 nerve growth factor Drugs 0.000 description 516
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 104
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 description 102
- 230000001965 increasing effect Effects 0.000 description 25
- 230000005764 inhibitory process Effects 0.000 description 22
- 230000014511 neuron projection development Effects 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 17
- 230000004663 cell proliferation Effects 0.000 description 15
- 239000000014 opioid analgesic Substances 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000005021 gait Effects 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000001473 noxious effect Effects 0.000 description 3
- 102100037597 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 108010064884 trkA Receptor Proteins 0.000 description 2
- 102000015533 trkA Receptor Human genes 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 208000028572 Hereditary chronic pancreatitis Diseases 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010065016 Post-traumatic pain Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 1
- 201000000887 hereditary sensory and autonomic neuropathy type 5 Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004070 myogenic differentiation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000008050 pain signaling Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41883210P | 2010-12-01 | 2010-12-01 | |
| US61/418,832 | 2010-12-01 | ||
| PCT/US2011/062963 WO2012075340A2 (en) | 2010-12-01 | 2011-12-01 | Anti-ngf compositions and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2821515A1 true CA2821515A1 (en) | 2012-06-07 |
Family
ID=46162451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2821515A Abandoned CA2821515A1 (en) | 2010-12-01 | 2011-12-01 | Anti-ngf compositions and use thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US9783602B2 (enExample) |
| EP (2) | EP2646468B1 (enExample) |
| JP (2) | JP6190723B2 (enExample) |
| KR (2) | KR102025848B1 (enExample) |
| CN (1) | CN103619879A (enExample) |
| AU (2) | AU2011336470B8 (enExample) |
| CA (1) | CA2821515A1 (enExample) |
| MX (1) | MX359070B (enExample) |
| NZ (1) | NZ611076A (enExample) |
| WO (1) | WO2012075340A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9498530B2 (en) * | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| SI2263692T1 (sl) * | 2002-12-24 | 2020-10-30 | Rinat Neuroscience Corp. | Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo |
| CN102224153B (zh) | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| LT3106463T (lt) | 2008-10-22 | 2018-06-25 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| NZ611076A (en) | 2010-12-01 | 2015-09-25 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| HRP20211873T1 (hr) * | 2011-05-20 | 2022-03-04 | H. Lundbeck A/S | Proizvodnja visoke čistoće proteina s više podjedinica kao što su protutijela u transformiranim mikrobima kao što je pichia pastoris |
| US10150968B2 (en) | 2011-08-19 | 2018-12-11 | Alderbio Holdings Llc | Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9062104B2 (en) | 2013-03-14 | 2015-06-23 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| US9732150B2 (en) * | 2013-03-14 | 2017-08-15 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| JP6557664B2 (ja) * | 2014-01-06 | 2019-08-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 一価の血液脳関門シャトルモジュール |
| AU2015346046B2 (en) | 2014-11-16 | 2020-06-25 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
| WO2016168757A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| MY193078A (en) | 2015-06-24 | 2022-09-26 | Hoffmann La Roche | Anti-transferrin receptor antibodies with tailored affinity |
| CN108137697A (zh) | 2015-10-02 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| CN114671940B (zh) * | 2016-03-18 | 2023-09-26 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子突变体 |
| TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| JP2019515671A (ja) | 2016-04-15 | 2019-06-13 | アルダー バイオファーマシューティカルズ、インコーポレイテッド | 抗ｐａｃａｐ抗体及びそれらの使用 |
| SI3800189T1 (sl) | 2016-05-18 | 2023-11-30 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo (1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018237287A1 (en) * | 2017-06-22 | 2018-12-27 | Apexigen, Inc. | Anti-vista antibodies and methods of use |
| JP7356970B2 (ja) * | 2017-06-25 | 2023-10-05 | システィミューン， インク． | 多重特異性抗体とその作製及び使用方法 |
| WO2019005641A1 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF |
| CA3076662A1 (en) * | 2017-09-25 | 2019-03-28 | Ondrej SLABY | Methods for treating degenerative disc disease and chronic lower back pain |
| CN114751982B (zh) * | 2017-12-15 | 2023-06-23 | 安源医药科技（上海）有限公司 | 抗人ngf抗体及其制备方法和用途 |
| AR114110A1 (es) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
| WO2019178516A1 (en) | 2018-03-16 | 2019-09-19 | SEN-JAM Pharmaceutical LLC | Methods and compositions to treat enteropathic arthritis |
| WO2019191125A1 (en) * | 2018-03-27 | 2019-10-03 | Systimmune, Inc. | Methods of making and using guidance and navigation control proteins |
| CN108623687A (zh) * | 2018-04-17 | 2018-10-09 | 中山康方生物医药有限公司 | 神经生长因子的单克隆抗体及其编码基因和应用 |
| WO2020248942A1 (zh) * | 2019-06-10 | 2020-12-17 | 山东博安生物技术有限公司 | 抗β-NGF纳米抗体及其应用 |
| CN113527482B (zh) * | 2020-04-17 | 2023-07-21 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
| CN116178541B (zh) * | 2020-08-06 | 2025-09-30 | 熙源安健医药(北京)有限公司 | 抗ngf抗体及其抗原结合片段、其制备方法和应用 |
| MX2023003599A (es) * | 2020-09-28 | 2023-04-05 | Navrogen Inc | Composicion y uso de anticuerpos anti-mesotelina alternativamente formateados para el tratamiento del cancer. |
| CN115433278A (zh) * | 2021-06-05 | 2022-12-06 | 苏州缔码生物科技有限公司 | 结合cs1蛋白兔重组单克隆抗体及应用 |
| AU2023365813A1 (en) * | 2022-10-18 | 2025-05-22 | Oncoresponse, Inc. | Lilrb2 antibody products and methods |
| AU2024271605A1 (en) * | 2023-05-12 | 2025-11-13 | BioNTech SE | Antibodies capable of binding to ox40, variants thereof and uses thereof |
| WO2024243049A2 (en) * | 2023-05-19 | 2024-11-28 | Ltz Therapeutics Inc. | Antibodies and uses thereof |
| CN119192353B (zh) * | 2024-05-22 | 2025-06-20 | 宁夏大学 | 抗bhv-1的重组兔单克隆抗体及双抗体夹心elisa试剂和应用 |
| CN118465261B (zh) * | 2024-07-09 | 2024-10-15 | 浙江康佰裕生物科技有限公司 | 一种检测逆转录病毒载体物理滴度的elisa试剂盒 |
| CN118702814A (zh) * | 2024-07-12 | 2024-09-27 | 麦里生物科技(上海)有限公司 | 一种抗ngf单克隆抗体及其应用 |
Family Cites Families (353)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4230691A (en) | 1978-05-23 | 1980-10-28 | The Massachusetts General Hospital | Nerve growth factor antibody and process |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| US5683894A (en) | 1988-04-29 | 1997-11-04 | University Of California | Recombinant nerve growth factor |
| US6440928B1 (en) | 1988-12-06 | 2002-08-27 | Colorado State University Research Foundation | Method for treating diabetic neuropathy with NGF |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| US6262239B1 (en) | 1989-05-18 | 2001-07-17 | Yeda Research And Development Co., Ltd. | TNF receptor-specific antibodies |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5656435A (en) | 1989-08-28 | 1997-08-12 | Takeda Chemical Industries, Ltd. | Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof |
| US5180820A (en) | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US6566091B1 (en) | 1990-09-25 | 2003-05-20 | Genentech, Inc. | Neurotrophic factor |
| US6506728B2 (en) | 1990-09-25 | 2003-01-14 | Genentech, Inc. | Methods using a novel neurotrophic factor, NT-4 |
| US5604202A (en) | 1990-11-13 | 1997-02-18 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of NGF growth factors to treat drug-induced neuropathy |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US6140120A (en) | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| WO1994021293A1 (en) | 1993-03-19 | 1994-09-29 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| EP1179350A3 (en) | 1993-08-12 | 2003-01-02 | Cytotherapeutics, Inc. | Encapsulated cell system for implantation into the human CNS |
| US5908623A (en) | 1993-08-12 | 1999-06-01 | Cytotherapeutics, Inc. | Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| US6562596B1 (en) | 1993-10-06 | 2003-05-13 | Amgen Inc. | Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5753225A (en) | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
| EP0734438A4 (en) | 1993-12-17 | 1998-12-23 | Spinal Cord Society | METHOD FOR INDUCING DNA SYNTHESIS IN NEURONES |
| GB9402331D0 (en) | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
| US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
| US6024734A (en) | 1994-03-31 | 2000-02-15 | Brewitt; Barbara A. | Treatment methods using homeopathic preparations of growth factors |
| US6291247B1 (en) | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
| US5728803A (en) | 1994-06-03 | 1998-03-17 | Genentech, Inc. | Pantropic neurotrophic factors |
| US7144983B1 (en) | 1997-02-03 | 2006-12-05 | Genentech, Inc. | Pantropic neurotrophic factors |
| US5840576A (en) | 1994-07-20 | 1998-11-24 | Cytotherapeutics, Inc. | Methods and compositions of growth control for cells encapsulated within bioartificial organs |
| WO1996004925A1 (en) | 1994-08-12 | 1996-02-22 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6271205B1 (en) | 1994-09-21 | 2001-08-07 | University Of Massachusetts Medical Center | Cancer treatment by expression of differentiation factor receptor |
| US5798448A (en) | 1994-10-27 | 1998-08-25 | Genentech, Inc. | AL-1 neurotrophic factor antibodies |
| US6096716A (en) | 1994-12-12 | 2000-08-01 | The Board Of Regents, The University Of Texas System | Liposome-mediated transfection of central nervous system cells |
| US6211142B1 (en) | 1995-03-10 | 2001-04-03 | Genentech, Inc. | Compositions comprising gas6 polypeptides and articles of manufacture comprising the same |
| US5688911A (en) | 1995-05-03 | 1997-11-18 | Schneider; Rainer | Trk neurotrophin binding motifs |
| US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| US5731284A (en) | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
| US20020090682A1 (en) | 1995-10-23 | 2002-07-11 | Tracy Willson | Novel haemopoietin receptor and genetic sequences encoding same |
| US6610296B2 (en) | 1995-10-26 | 2003-08-26 | Genentech, Inc. | Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin |
| GB9525180D0 (en) | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
| US6406710B1 (en) | 1996-01-16 | 2002-06-18 | Nikos Panayotatos | Protein occlusion for delivery of small molecules |
| EP0886649A4 (en) | 1996-01-16 | 2002-11-20 | Nikos Panayotatos | PROTEIN OCCLUSION FOR THE SUPPLY OF SMALL MOLECULES |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| GB9608335D0 (en) | 1996-04-23 | 1996-06-26 | Univ Kingston | Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379 |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| AU718500B2 (en) | 1997-01-23 | 2000-04-13 | Sumitomo Pharmaceuticals Company, Limited | Remedies for diabetes |
| US6777196B2 (en) | 1997-02-18 | 2004-08-17 | Genentech, Inc. | Neurturin receptor |
| US6365373B2 (en) | 1997-04-25 | 2002-04-02 | Genentech, Inc. | Nucleic acids encoding NGF variants |
| US7452863B1 (en) | 1997-04-29 | 2008-11-18 | Genentech, Inc. | NGF variants |
| BR9810369A (pt) | 1997-06-30 | 2000-09-05 | Rhone Poulenc Rorer Sa | Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação |
| ATE290403T1 (de) | 1997-06-30 | 2005-03-15 | Roussy Inst Gustave | Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| US5990129A (en) | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| US5928174A (en) | 1997-11-14 | 1999-07-27 | Acrymed | Wound dressing device |
| US7282482B2 (en) | 1998-04-08 | 2007-10-16 | The Regents Of The University Of California | NGF for the prevention of demyelination in the nervous system |
| GB9807781D0 (en) | 1998-04-09 | 1998-06-10 | Univ Bristol | Therapeutic agent |
| US20030096753A1 (en) | 1998-04-09 | 2003-05-22 | Robertson Alan George Simpson | Therapeutic agent |
| US6866842B1 (en) | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
| US6428579B1 (en) | 1998-07-01 | 2002-08-06 | Brown University Research Foundation | Implantable prosthetic devices coated with bioactive molecules |
| WO2000016799A1 (en) | 1998-09-23 | 2000-03-30 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating chronic pain |
| US6506599B1 (en) | 1999-10-15 | 2003-01-14 | Tai-Wook Yoon | Method for culturing langerhans islets and islet autotransplantation islet regeneration |
| US6680292B1 (en) | 1998-11-20 | 2004-01-20 | The Salk Institute For Biological Studies | Pharmaceutical composition comprising ribavirin and growth factors and methods of use |
| US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
| US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| ATE412433T1 (de) | 1999-02-12 | 2008-11-15 | Scripps Research Inst | Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien |
| US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
| US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| US20020177120A1 (en) | 1999-06-04 | 2002-11-28 | Kathryn J. Elliott | Assays for apotosis modulators |
| US20030152562A1 (en) | 2001-10-23 | 2003-08-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Vitro micro-organs, and uses related thereto |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| CA2386239A1 (en) | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying rna binding compounds |
| KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
| US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| US20040058393A1 (en) | 2000-04-17 | 2004-03-25 | Naoshi Fukishima | Agonist antibodies |
| US7473555B2 (en) | 2000-04-27 | 2009-01-06 | Geron Corporation | Protocols for making hepatocytes from embryonic stem cells |
| US6686196B2 (en) | 2000-05-03 | 2004-02-03 | University Of Washington | Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof |
| CA2412494C (en) | 2000-06-22 | 2012-10-23 | Genentech, Inc. | Agonist anti-trk-c monoclonal antibodies |
| ATE499103T1 (de) | 2000-07-07 | 2011-03-15 | Spectrum Pharmaceuticals Inc | Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen |
| US6719970B1 (en) | 2000-07-10 | 2004-04-13 | Alkermes Controlled Therapeutics, Inc. | Method of generating cartilage |
| US20020164333A1 (en) | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| WO2002003922A2 (en) | 2000-07-11 | 2002-01-17 | Lipps Binie V | Synthetic peptide for neurological disorders |
| US20070122904A1 (en) | 2000-09-29 | 2007-05-31 | Unisearch Limited | Method and apparatus for culturing cells |
| EP2351838A1 (en) | 2000-10-20 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Crosslinking agonistic antibodies |
| US20020128179A1 (en) | 2000-12-01 | 2002-09-12 | Tacon William C. | Shaped microparticles for pulmonary drug delivery |
| US20020115173A1 (en) | 2000-12-11 | 2002-08-22 | Children's Medical Center Corporation | Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity |
| US7169568B2 (en) | 2000-12-18 | 2007-01-30 | New York University | Method for screening molecules that exert a neurotrophic effect through activation of neurotrophin receptors |
| DE10101546B4 (de) | 2001-01-15 | 2005-04-28 | Man Technologie Gmbh | Verfahren zur Herstellung einer hochtemperaturfesten Faserverbundkeramik und so hergestellte Bauteile |
| US6602241B2 (en) | 2001-01-17 | 2003-08-05 | Transvascular, Inc. | Methods and apparatus for acute or chronic delivery of substances or apparatus to extravascular treatment sites |
| US20040115671A1 (en) | 2001-01-18 | 2004-06-17 | Zlokovic Berislav V | Gene expression profiling of endothelium in alzheimer's disease |
| US6596262B2 (en) | 2001-02-15 | 2003-07-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6749845B2 (en) | 2001-02-15 | 2004-06-15 | Aeropharm Technology, Inc. | Modulated release particles for lung delivery |
| US6544497B2 (en) | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6475468B2 (en) | 2001-02-15 | 2002-11-05 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6485707B2 (en) | 2001-02-15 | 2002-11-26 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US6551578B2 (en) | 2001-02-15 | 2003-04-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
| CA2441588A1 (en) | 2001-03-23 | 2002-10-03 | Biopharm Gesellschaft Zue Biotechnologischen Entwicklung Von Pharmaka Mbh | Use of cytokines of the tgf-.beta. superfamily for the treatment and diagnosis of skin related disorders |
| JP2004531250A (ja) | 2001-04-06 | 2004-10-14 | ビオ・ビジョン・アーゲー | 慢性痴呆疾患の検出方法、関連ペプチドおよび検出試薬 |
| CA2447986A1 (en) | 2001-05-25 | 2002-12-05 | Cornell Research Foundation, Inc. | High affinity ligand for p75 neurotrophin receptor |
| JP2002348234A (ja) | 2001-05-28 | 2002-12-04 | Purotekku:Kk | 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤 |
| CN1684708A (zh) | 2001-05-30 | 2005-10-19 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| WO2002102232A2 (en) | 2001-06-14 | 2002-12-27 | The Regents Of The University Of California | A novel signaling pathway for the production of inflammatory pain and neuropathy |
| US7063860B2 (en) | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| EP1456345B1 (en) | 2001-08-22 | 2016-07-20 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
| JP2005512592A (ja) | 2001-12-21 | 2005-05-12 | マウント・シナイ・ホスピタル | 細胞性組成物ならびに細胞性組成物の作製法および細胞性組成物の使用法 |
| US20050142539A1 (en) | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
| EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
| IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| CA2369810C (en) | 2002-01-30 | 2007-08-07 | 1474791 Ontario Limited | Method of treating pain |
| US20030232419A1 (en) | 2002-02-04 | 2003-12-18 | Kolodkin Alex L. | Molecules interacting with CASL (MICAL) polynucleotides, polypeptides, and methods of using the same |
| US8491896B2 (en) | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| AU2003213647A1 (en) | 2002-02-27 | 2003-09-09 | Emory University | Multimeric binding complexes |
| US20050220774A1 (en) | 2002-03-18 | 2005-10-06 | Tony Peled | Methods of inducing differentiation in ex vivo expanded stem cells |
| US20040009589A1 (en) | 2002-03-26 | 2004-01-15 | Shulamit Levenberg | Endothelial cells derived from human embryonic stem cells |
| US20060093589A1 (en) | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
| ATE405295T1 (de) | 2002-05-01 | 2008-09-15 | Univ Florida | Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine |
| AU2003243781A1 (en) | 2002-06-24 | 2004-01-06 | Amniotech, Inc. | Amniotic membrane mediated delivery of bioactive molecules |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| JP2005537244A (ja) | 2002-06-28 | 2005-12-08 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法 |
| AU2003256613A1 (en) | 2002-07-19 | 2004-02-09 | Amgen Inc. | Protein conjugates with a water-soluble biocompatible, biogradable polymer |
| US8263375B2 (en) | 2002-12-20 | 2012-09-11 | Acea Biosciences | Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology |
| US7745151B2 (en) | 2002-08-02 | 2010-06-29 | Children's Medical Center Corporation | Methods of determining binding between Nogo receptor and p75 neurotrophin receptor |
| US20050074865A1 (en) | 2002-08-27 | 2005-04-07 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| US20060185025A1 (en) | 2002-10-04 | 2006-08-17 | Kirin Beer Kabushiki Kaisha | Human artificial chromosome (hac) vector |
| WO2004032852A2 (en) | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
| ZA200502612B (en) | 2002-10-08 | 2007-07-25 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| AU2003304238A1 (en) | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
| US20040209801A1 (en) | 2002-10-22 | 2004-10-21 | Brand Stephen J. | Treatment of diabetes |
| FR2846426B1 (fr) | 2002-10-28 | 2004-12-10 | Bio Merieux | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
| US20050054097A1 (en) | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
| ES2380055T3 (es) | 2002-12-20 | 2012-05-08 | H. Lundbeck A/S | Modulación de la actividad de neurotrofinas; método de escrutinio |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| SI2263692T1 (sl) * | 2002-12-24 | 2020-10-30 | Rinat Neuroscience Corp. | Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| US20060147932A1 (en) | 2003-01-18 | 2006-07-06 | Alun Davies | Methods of screening for modulators of nerve growth factor |
| WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR20050111598A (ko) | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| WO2004085712A2 (en) | 2003-03-24 | 2004-10-07 | Penn State Research Foundation | Multi-functional polymeric materials and their uses |
| US20060193825A1 (en) | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| WO2004101017A2 (de) | 2003-05-16 | 2004-11-25 | Blue Membranes Gmbh | Biokompatibel beschichtete medizinische implantate |
| CA2527878A1 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| WO2005005475A2 (en) | 2003-07-10 | 2005-01-20 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Appl proteins as rab5 effectors |
| CN102358903B (zh) * | 2003-07-15 | 2017-04-26 | 安姆根有限公司 | 作为选择性ngf途径抑制剂的人抗ngf中和抗体 |
| US20050027110A1 (en) | 2003-07-24 | 2005-02-03 | Michael Russell | Drug delivery in the nervous system |
| EP1500399A1 (en) | 2003-07-24 | 2005-01-26 | Institut Pasteur | Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases |
| US7205387B2 (en) | 2003-08-28 | 2007-04-17 | Agency For Science, Technology And Research | Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist |
| US20050085417A1 (en) | 2003-10-16 | 2005-04-21 | Thomas Jefferson University | Compounds and methods for diagnostic imaging and therapy |
| US7846891B2 (en) | 2003-10-17 | 2010-12-07 | Massachusetts Institute Of Technology | Self-assembling peptides for regeneration and repair of neural tissue |
| ES2630224T3 (es) | 2003-10-22 | 2017-08-18 | Keck Graduate Institute | Métodos para sintetizar polipéptidos heteromultiméricos en levadura con el uso de una estrategia de apareamiento haploide |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| JP5039383B2 (ja) | 2003-11-30 | 2012-10-03 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 免疫モジュレーションのための方法および薬剤ならびに免疫モジュレーターの同定方法 |
| US8093205B2 (en) | 2003-12-01 | 2012-01-10 | Medtronic, Inc. | Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis |
| US20050123526A1 (en) | 2003-12-01 | 2005-06-09 | Medtronic Inc. | Administration of growth factors for neurogenesis and gliagenesis |
| EP1695061A4 (en) | 2003-12-16 | 2008-02-20 | Childrens Medical Center | METHOD OF TREATING NEUROLOGICAL DISORDERS |
| AU2004309347B2 (en) | 2003-12-19 | 2010-03-04 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
| DE10360483B4 (de) | 2003-12-22 | 2007-11-15 | Scil Proteins Gmbh | Expressionsvektor und dessen Verwendung |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| WO2005065721A2 (en) | 2003-12-30 | 2005-07-21 | Board Of Regents, The University Of Texas System | Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex |
| US8562988B2 (en) | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| US8883160B2 (en) | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US7901680B2 (en) | 2005-10-19 | 2011-03-08 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) vaccines for cancer therapy |
| US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| DK2206728T3 (en) * | 2004-04-07 | 2018-04-23 | Rinat Neuroscience Corp | METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY |
| WO2005100589A2 (en) | 2004-04-19 | 2005-10-27 | Hankins William D | Kinetic process for the detection, diagnosis, processing, and monitoring of clonal cell populations |
| ITRM20040212A1 (it) | 2004-04-30 | 2004-07-30 | Lay Line Genomics Spa | Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce. |
| CN1997382A (zh) | 2004-05-05 | 2007-07-11 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
| JP2008500830A (ja) | 2004-06-01 | 2008-01-17 | ドマンティス リミテッド | 増加した血清半減期を有する二重特異性融合抗体 |
| JP2008501725A (ja) | 2004-06-10 | 2008-01-24 | ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | グリカンに特異的な受容体として機能するインテグリンを介したグリコシルホスファチジルイノシトールグリカンシグナル伝達 |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| WO2006001023A2 (en) | 2004-06-28 | 2006-01-05 | Yeda Research And Development Co. Ltd | Chimeric proteins and uses thereof |
| US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| AU2005278136A1 (en) | 2004-08-02 | 2006-03-02 | Children's Medical Center Corporation | Platelet biomarkers for cancer |
| PT1773885E (pt) | 2004-08-05 | 2010-07-21 | Genentech Inc | Antagonistas anti-cmet humanizados |
| KR100876771B1 (ko) | 2004-08-17 | 2009-01-07 | 삼성전자주식회사 | 무선 통신 시스템에서 제어 정보 압축 방법과 스캐닝 정보 송수신 방법 및 장치 |
| US20060068469A1 (en) | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
| JP5089388B2 (ja) | 2004-09-01 | 2012-12-05 | アラーガン、インコーポレイテッド | 分解可能なクロストリジウム毒素 |
| MX2007003078A (es) * | 2004-09-14 | 2007-05-16 | Novartis Vaccines & Diagnostic | Compuestos de imidazoquinolina. |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| US7629325B2 (en) | 2004-10-11 | 2009-12-08 | Technion Research & Development Foundation Ltd. | Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy |
| US20060159666A1 (en) | 2004-10-22 | 2006-07-20 | Willing Alison E | Method of potentiating inflammatory and immune modulation for cell and drug therapy |
| JPWO2006057152A1 (ja) | 2004-11-08 | 2008-06-05 | 小野薬品工業株式会社 | タンパク質分解酵素阻害化合物からなる糖尿病治療剤 |
| WO2006055841A2 (en) | 2004-11-19 | 2006-05-26 | University Of Florida Research Foundation, Inc. | Indefinite culture of human adult glia without immortalization and therapeutic uses thereof |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| SI1844337T1 (sl) | 2005-01-24 | 2013-11-29 | Pepscan Systems B.V. | Povezovalne spojine, imunogene spojine in peptidomimetiki |
| RU2406728C2 (ru) * | 2005-01-24 | 2010-12-20 | Медиммун Лимитэд | Партнеры специфического связывания с ngf |
| BRPI0606934A2 (pt) | 2005-01-25 | 2017-07-11 | Cell Therapeutics Inc | Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado |
| WO2006084173A1 (en) | 2005-02-04 | 2006-08-10 | The Johns Hopkins University | Electroporation gene therapy gun system |
| US20060182724A1 (en) | 2005-02-15 | 2006-08-17 | Riordan Neil H | Method for expansion of stem cells |
| US20100172871A1 (en) | 2005-02-17 | 2010-07-08 | Flannery John G | Muller Cell Specific Gene Therapy |
| US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| WO2006094192A2 (en) | 2005-03-03 | 2006-09-08 | Immunomedics, Inc. | Humanized l243 antibodies |
| CN101180397A (zh) | 2005-03-09 | 2008-05-14 | 得克萨斯大学体系董事会 | 用于癌症治疗基因的肿瘤选择性和高效率表达的新型hTMC启动子和载体 |
| CA2602951A1 (en) | 2005-03-23 | 2006-09-28 | Bio-Rad Laboratories, Inc. | Diverse chemical libraries bound to small particles with paramagnetic properties |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| BRPI0612972A2 (pt) | 2005-04-22 | 2010-12-14 | Genentech Inc | mÉtodo para tratar doenÇa de alzheimer, mÉtodo para tratar demÊncia, artigo de fabricaÇço e usos de um anticorpo cd20 |
| BRPI0611009A2 (pt) | 2005-06-02 | 2010-08-10 | Galaxy Biotech Llc | usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização |
| GT200600240A (es) | 2005-06-06 | 2007-03-14 | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| DE602005012812D1 (de) | 2005-06-13 | 2009-04-02 | Primm Srl | Heterodimere Peptide mit NGF Aktivität und deren Verwendung zur Behandlung von neurodegenerativen Krankheiten |
| US8877714B2 (en) | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
| EP3351269B1 (en) | 2005-06-14 | 2020-01-29 | Amgen Inc. | Self-buffering protein formulations |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| RU2008110060A (ru) | 2005-08-15 | 2009-09-27 | Арана Терапьютикс Лимитед (Au) | Сконструированные антитела с каркасными участками приматов нового света |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2620306A1 (en) | 2005-08-25 | 2007-03-01 | Repair Technologies, Inc. | Devices, compositions and methods for the protection and repair of cells and tissues |
| CA2623648C (en) | 2005-09-21 | 2018-05-22 | The Regents Of The University Of California | Systems, compositions, and methods for local imaging and treatment of pain |
| US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| JP2009514904A (ja) | 2005-11-07 | 2009-04-09 | ユニバーシティ オブ コペンハーゲン | ニューロトロフィン由来ペプチド配列 |
| US20090220466A1 (en) | 2005-12-08 | 2009-09-03 | Mariusz Ratajczak | Very small embryonic-like (vsel) stem cells and methods of isolating and using the same |
| WO2007070983A1 (en) | 2005-12-22 | 2007-06-28 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| WO2007078922A2 (en) | 2005-12-30 | 2007-07-12 | Neurotech Usa Inc. | Micronized device for the delivery of biologically active molecules and methods of use thereof |
| US7342146B2 (en) | 2006-01-11 | 2008-03-11 | Industrial Technology Research Institute | Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein |
| KR100784485B1 (ko) | 2006-01-18 | 2007-12-11 | 한국과학기술연구원 | 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도 |
| US8163018B2 (en) | 2006-02-14 | 2012-04-24 | Warsaw Orthopedic, Inc. | Treatment of the vertebral column |
| PT1988910T (pt) | 2006-02-28 | 2018-02-07 | Kodiak Sciences Inc | Acriloiloxietilfosforilcolina contendo conjugados de polímeros e sua preparação |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| KR100746962B1 (ko) | 2006-04-04 | 2007-08-07 | 한국과학기술연구원 | 온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도 |
| WO2007127803A2 (en) | 2006-04-25 | 2007-11-08 | The Regents Of The University Of California | Administration of growth factors for the treatment of cns disorders |
| CA2651285C (en) | 2006-05-15 | 2014-08-19 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| WO2008045140A1 (en) | 2006-05-19 | 2008-04-17 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
| US8623610B2 (en) | 2006-05-22 | 2014-01-07 | California Institute Of Technology | Chondroitin sulfate binding proteins and modulators thereof |
| WO2007146811A2 (en) | 2006-06-09 | 2007-12-21 | University Of Miami | Assessment of cellular composition and fractional viability and uses thereof |
| US8475788B2 (en) | 2006-06-14 | 2013-07-02 | Stemnion, Inc. | Methods of treating spinal cord injury and minimizing scarring |
| EP2048229B1 (en) | 2006-07-07 | 2016-02-17 | Kyowa Hakko Kirin Co., Ltd. | Human artificial chromosome (hac) vector, and human cell pharmaceutical comprising human artificial chromosome (hac) vector |
| US20080132427A1 (en) | 2006-07-21 | 2008-06-05 | Yao Zhuang | Cell systems and methods for detecting proliferation acitvity |
| DE602006013809D1 (de) | 2006-07-24 | 2010-06-02 | Facultad De Medicina Universid | Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden |
| EP2068866A4 (en) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| WO2008021196A2 (en) | 2006-08-09 | 2008-02-21 | The Mclean Hospital Corporation | Methods and compositions for the treatment of medical disorders |
| JP2010501200A (ja) | 2006-08-25 | 2010-01-21 | デューク・ユニヴァーシティ | ｍｉｃｒｏＲＮＡの内在性ｍＲＮＡ標的のインビボでの同定のための方法 |
| US20090004742A1 (en) | 2006-11-01 | 2009-01-01 | Duke University | Selection of antigen-specific t cells |
| GB0622688D0 (en) | 2006-11-14 | 2006-12-27 | Diosamine Dev Corp | Novel compounds |
| JP5576659B2 (ja) | 2006-12-05 | 2014-08-20 | ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング／ マギル ユニバーシティ | Ｔｒｋレセプター調節因子の使用方法 |
| US20080139790A1 (en) | 2006-12-08 | 2008-06-12 | Jennings Philip A | Chimeric antibodies |
| SI3225251T1 (sl) | 2006-12-21 | 2020-03-31 | H. Lundbeck A/S | Modulacija aktivnosti pronevrotrofinov |
| AR064501A1 (es) | 2006-12-22 | 2009-04-08 | Genentech Inc | Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos |
| WO2008086079A2 (en) | 2007-01-03 | 2008-07-17 | Medtronic, Inc. | Compositions comprising rnai and a neurotrophic factor and uses thereof |
| US20100009997A1 (en) | 2007-01-12 | 2010-01-14 | Biomarin Pharmaceutical Inc. | Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug |
| NZ578696A (en) | 2007-02-02 | 2012-01-12 | Baylor Res Inst | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
| AU2008218184B2 (en) | 2007-02-02 | 2013-01-10 | Baylor Research Institute | Activation of human antigen-presenting cells through CLEC-6 |
| WO2008097817A2 (en) | 2007-02-02 | 2008-08-14 | Baylor Research Institute | Multivariable antigens complexed with targeting humanized monoclonal antibody |
| WO2008101215A1 (en) | 2007-02-16 | 2008-08-21 | Varian Medical Systems Technologies, Inc. | Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo |
| CA2678451A1 (en) | 2007-02-20 | 2008-08-28 | Robert A. Horlick | Somatic hypermutation systems |
| JP2010519316A (ja) | 2007-02-23 | 2010-06-03 | ベイラー リサーチ インスティテュート | デクチン−１を介したヒト抗原提示細胞の活性化の治療への応用 |
| US20110268776A1 (en) | 2007-04-25 | 2011-11-03 | Schapira Jay N | Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration |
| TWI501976B (zh) | 2007-05-21 | 2015-10-01 | Alder Biopharmaceuticals Inc | 抗ＴＮＦ－α之抗體及其用途 |
| US9056905B2 (en) | 2007-05-21 | 2015-06-16 | Alderbio Holdings Llc | Antibodies to TNF-α and use thereof |
| KR101829776B1 (ko) | 2007-05-21 | 2018-02-19 | 앨더바이오 홀딩스 엘엘씨 | Ｉｌ-６에 대한 항체 및 이의 용도 |
| AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| US20090175847A1 (en) | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
| US20090232801A1 (en) | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| KR100968591B1 (ko) | 2007-06-14 | 2010-07-08 | 한국과학기술연구원 | 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도 |
| US20080318314A1 (en) | 2007-06-20 | 2008-12-25 | Valentin Fulga | Production from blood of cells of neural lineage |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| CA3113365A1 (en) | 2007-07-09 | 2009-01-15 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| US7988967B2 (en) | 2007-08-10 | 2011-08-02 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
| WO2009032148A1 (en) | 2007-08-29 | 2009-03-12 | Tufts University | Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
| PL2202245T3 (pl) * | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
| WO2009072005A2 (en) | 2007-10-15 | 2009-06-11 | Centre National De La Recherche Scientifique - C.N.R.S. | Cxcl12 gamma a chemokine and uses thereof |
| US7960145B2 (en) | 2007-11-08 | 2011-06-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| CA2705542A1 (en) | 2007-11-13 | 2009-05-22 | Sapphire Energy, Inc. | Production of fc-fusion polypeptides in eukaryotic algae |
| BRPI0819932A2 (pt) | 2007-12-13 | 2019-07-30 | Glaxo Group Ltd | composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável. |
| AU2008337100B2 (en) | 2007-12-17 | 2013-02-28 | Pfizer Limited | Treatment of interstitial cystitis |
| US20110189206A1 (en) | 2008-01-03 | 2011-08-04 | Barbas Iii Carlos F | Antibody Targeting Through a Modular Recognition Domain |
| WO2009088054A1 (ja) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | 精巣の疼痛又は不快感行動及び頻尿併発モデル動物 |
| EP2249856B1 (en) | 2008-01-30 | 2013-11-06 | Baylor College Of Medicine | Peptides that target dorsal root ganglion neurons |
| CN101939337B (zh) | 2008-02-04 | 2016-03-09 | 雷莱恩基因组有限公司 | 抗trka抗体及其衍生物 |
| JP5634272B2 (ja) | 2008-03-14 | 2014-12-03 | ヒューマンザイム リミテッド | ヒト細胞発現系を用いる真正ヒトタンパク質の組換え生産 |
| WO2009118411A2 (en) | 2008-03-28 | 2009-10-01 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP5715045B2 (ja) | 2008-04-27 | 2015-05-07 | ハー・ルンドベック・アクチエゼルスカベット | ソルチリンに対する特異的リガンドの設計 |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PE20100054A1 (es) | 2008-06-03 | 2010-03-03 | Abbott Lab | Inmunoglobulina con dominio variable dual |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| EP2307042B1 (en) | 2008-06-25 | 2014-03-26 | H. Lundbeck A/S | Modulation of the trpv : vps10p-domain receptor system for the treatment of pain |
| MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| CN101633694B (zh) | 2008-07-24 | 2012-08-29 | 厦门北大之路生物工程有限公司 | 抗鼠神经生长因子(ngf)的多克隆抗体的制备方法及其应用 |
| EP2331090B1 (en) | 2008-09-19 | 2018-01-03 | Pfizer Inc. | Stable liquid antibody formulation |
| US8084222B2 (en) | 2008-09-26 | 2011-12-27 | Eureka Therapeutics, Inc. | Methods for generating host cells |
| US9320878B2 (en) | 2008-10-07 | 2016-04-26 | Tuo Jin | Phase-transition polymeric microneedles |
| SG195557A1 (en) | 2008-10-22 | 2013-12-30 | Genentech Inc | Modulation of axon degeneration |
| US20100104652A1 (en) | 2008-10-27 | 2010-04-29 | University Of Arkansas | Use of advanced nanomaterials for increasing sepecific cell functions |
| KR20160132133A (ko) | 2008-10-31 | 2016-11-16 | 신세스 게엠바하 | 줄기 세포를 활성화시키는 방법 및 장치 |
| EP3153524B1 (en) | 2008-12-03 | 2025-04-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| KR20110102930A (ko) | 2008-12-31 | 2011-09-19 | 케이씨아이 라이센싱 인코포레이티드 | 신경 조직에 유체 흐름을 제공하기 위한 시스템 |
| CN102361971A (zh) | 2009-01-23 | 2012-02-22 | Ns基因公司 | 改善的细胞系以及在胶囊化细胞生物递送中的用途 |
| NZ596839A (en) * | 2009-05-04 | 2014-01-31 | Abbott Res Bv | Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
| TW201114436A (en) | 2009-07-02 | 2011-05-01 | Glaxo Group Ltd | Polypeptides and method of treatment |
| US20110033463A1 (en) | 2009-08-06 | 2011-02-10 | Medtronic, Inc. | Apheresis, administration of agent, or combination thereof |
| IL264336B2 (en) | 2009-08-11 | 2024-02-01 | Genentech Inc | Production of proteins in cell culture medium without glutamine |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| EP3009455A1 (en) | 2009-09-16 | 2016-04-20 | Immunomedics Inc. | Class i anti-cea antibodies and uses thereof |
| US9155722B2 (en) | 2009-09-18 | 2015-10-13 | Protherics Salt Lake City, Inc. | Reconstitutable reverse thermal gelling polymers |
| US8753621B2 (en) | 2009-09-18 | 2014-06-17 | Protherics Salt Lake City, Inc. | BAB triblock polymers having improved release characteristics |
| AR078651A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2011085354A1 (en) | 2010-01-11 | 2011-07-14 | Center For Molecular Medicine And Immunology | Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma |
| CN105640501A (zh) | 2010-01-26 | 2016-06-08 | 迈克尔·A·埃文斯 | 用于去神经支配的方法、装置以及药剂 |
| US20110250206A1 (en) | 2010-02-11 | 2011-10-13 | Axtell Robert C | Markers for determination of patient responsiveness |
| PH12012501761A1 (en) | 2010-03-17 | 2012-11-12 | Abbott Res Bv | Anti-nerve growth factor (ngf) antibody compositions |
| CA2794499A1 (en) | 2010-04-01 | 2011-10-06 | Immumomedics, Inc. | Antibody-based depletion of antigen-presenting cells and dendritic cells |
| JP2013523153A (ja) | 2010-04-07 | 2013-06-17 | アッヴィ・インコーポレイテッド | ＴＮＦ−α結合タンパク質 |
| SG184089A1 (en) | 2010-04-12 | 2012-11-29 | Somalogic Inc | APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| PT3333188T (pt) | 2010-08-19 | 2022-03-28 | Zoetis Belgium S A | Anticorpos de anti-ngf e a sua utilização |
| CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| NZ611076A (en) | 2010-12-01 | 2015-09-25 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| WO2012088302A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| EP2655415A4 (en) | 2010-12-22 | 2016-03-09 | Abbvie Inc | THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF |
| US8668886B2 (en) | 2011-04-24 | 2014-03-11 | Therapeutic Proteins International, LLC | Separative bioreactor |
| WO2012153123A1 (en) | 2011-05-06 | 2012-11-15 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| GB2504887B (en) | 2011-05-06 | 2016-02-03 | Nvip Pty Ltd | Anti-Nerve growth factor antibodies and methods of preparing and using the same |
| ES2654111T3 (es) | 2011-08-05 | 2018-02-12 | Bioasis Technologies Inc. | Fragmentos p97 con actividad de transferencia |
| NO2743348T3 (enExample) | 2011-08-11 | 2018-06-09 | ||
| US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
| AU2013273115B2 (en) | 2012-06-08 | 2018-03-01 | Ichnos Sciences SA | Humanized anti-TrkA antibodies with amino acid substitutions |
| EP2674439B1 (en) | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
-
2011
- 2011-12-01 NZ NZ611076A patent/NZ611076A/en not_active IP Right Cessation
- 2011-12-01 EP EP11844615.2A patent/EP2646468B1/en not_active Not-in-force
- 2011-12-01 US US13/309,295 patent/US9783602B2/en not_active Expired - Fee Related
- 2011-12-01 EP EP18176490.3A patent/EP3434691A1/en not_active Withdrawn
- 2011-12-01 JP JP2013542189A patent/JP6190723B2/ja not_active Expired - Fee Related
- 2011-12-01 CA CA2821515A patent/CA2821515A1/en not_active Abandoned
- 2011-12-01 US US13/308,831 patent/US9783601B2/en not_active Expired - Fee Related
- 2011-12-01 MX MX2013006125A patent/MX359070B/es active IP Right Grant
- 2011-12-01 AU AU2011336470A patent/AU2011336470B8/en not_active Ceased
- 2011-12-01 US US13/309,153 patent/US8728473B2/en not_active Expired - Fee Related
- 2011-12-01 KR KR1020137017181A patent/KR102025848B1/ko not_active Expired - Fee Related
- 2011-12-01 US US13/308,665 patent/US8911734B2/en not_active Expired - Fee Related
- 2011-12-01 WO PCT/US2011/062963 patent/WO2012075340A2/en not_active Ceased
- 2011-12-01 CN CN201180066555.0A patent/CN103619879A/zh active Pending
- 2011-12-01 KR KR1020197027515A patent/KR20190112175A/ko not_active Ceased
-
2014
- 2014-11-05 US US14/533,645 patent/US9359432B2/en not_active Expired - Fee Related
-
2016
- 2016-10-14 US US15/294,016 patent/US10344083B2/en not_active Expired - Fee Related
- 2016-12-26 JP JP2016251053A patent/JP2017079779A/ja not_active Abandoned
-
2017
- 2017-07-28 AU AU2017208339A patent/AU2017208339A1/en not_active Abandoned
-
2019
- 2019-07-08 US US16/504,602 patent/US20200062837A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2646468B1 (en) | Anti-ngf compositions and use thereof | |
| AU2012258980B2 (en) | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers | |
| US9884909B2 (en) | Anti-NGF compositions and use thereof | |
| US10457727B2 (en) | Methods of preventing inflammation and treating pain using anti-NGF compositions | |
| AU2012258966B2 (en) | Anti-CGRP compositions and use thereof | |
| US10227402B2 (en) | Anti-NGF antibodies and anti-NGF antibody fragments | |
| US10221236B2 (en) | Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75 | |
| NZ618638B2 (en) | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20161130 |
|
| FZDE | Discontinued |
Effective date: 20220513 |
|
| FZDE | Discontinued |
Effective date: 20220513 |